Study confirms accuracy of non-invasive test for gastric cancer risk

A clinical study conducted by Homerton University Hospital NHS Foundation Trust, London, has confirmed the diagnostic accuracy of GastroPanel in identifying gastric cancer risk in patients with upper abdominal complaints. The study demonstrated that GastroPanel reliably identifies high-risk patients with over 90% accuracy, supporting early intervention and streamlined patient management. The findings have been published in BMJ Open Gastroenterology.

Designed as a first-line diagnostic tool, GastroPanel provides rapid preliminary assessments for dyspeptic complaints, helping to identify patients who require further specialist evaluation. By reducing the need for costly and invasive endoscopic procedures, it has the potential to alleviate pressure on overstretched NHS endoscopy services.

Jussi Hahtela, CEO of Biohit Oyj, emphasised the significance of early detection, stating: “GastroPanel benefits both patients and healthcare systems by enabling the rapid identification of gastric cancer risk conditions. Patients receive crucial information quickly and non-invasively, while healthcare providers benefit from a more cost-effective alternative to endoscopy.”

Panu Hendolin, Director of R&D at Biohit Oyj, highlighted its alignment with current clinical guidelines: “The British Society of Gastroenterology recommends non-invasive screening for patients at risk of gastric cancer, and GastroPanel meets that need perfectly. The study at Homerton Hospital, involving 324 patients, produced results consistent with previous international studies, further confirming its diagnostic accuracy.”

More information online